• 1
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90: 1371-1388.
  • 2
    Armstrong K, Quistberg DA, Micco E, Domchek S, Guerra C. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med. 2006; 166: 2260-2265.
  • 3
    Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol. 2004; 22: 4951-4957.
  • 4
    Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003; 95: 526-532.
  • 5
    Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999; 91: 1541-1548.
  • 6
    Hershman D, Sundararajan V, Jacobson JS, Heitjan DF, Neugut AI, Grann VR. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. J Clin Oncol. 2002; 20: 9-16.
  • 7
    Melnikow J, Birch S, Slee C, McCarthy TJ, Helms LJ, Kuppermann M. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis. Med Care. 2008; 46: 946-953.
  • 8
    Melnikow J, Kuenneth C, Helms LJ, et al. Chemoprevention: drug pricing and mortality: the case of tamoxifen. Cancer. 2006; 107: 950-958.
  • 9
    Kondo M, Hoshi SL, Toi M. Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan. Br J Cancer. 2009; 100: 281-290.
  • 10
    Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007; 99: 283-290.
  • 11
    Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007; 99: 272-282.
  • 12
    Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 2007; 99: 727-737.
  • 13
    Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol. 2001; 97: 855-866.
  • 14
    National Cancer Institute, SEER Program. Surveillance Epidemiology and End Results (SEER) Data 1973-2007. Bethesda, MD: National Cancer Institute; 2007.
  • 15
    Clay MG, Hislop TG, Kan L, Olivotto IA, Burhenne LJ. Screening mammography in British Columbia: 1988-1993. Am J Surg. 1994; 167: 490-492.
  • 16
    Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep. 2008; 56: 1-120.
  • 17
    Ballard-Barbash R, Taplin SH, Yankaskas BC, et al. Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. AJR Am J Roentgenol. 1997; 169: 1001-1008.
  • 18
    SobinLH, WittekindC, eds. TNM Classification of Malignant Tumors. 5thed. New York: Wiley & Sons, Inc.; 1997.
  • 19
    Vachon CM, Pankratz VS, Scott CG, et al. Longitudinal trends in mammographic percent density and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2007; 16: 921-928.
  • 20
    Spiegelman D, Colditz GA, Hunter D, Hertzmark E. Validation of the Gail et al model for predicting individual breast cancer risk. J Natl Cancer Inst. 1994; 86: 600-607.
  • 21
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997; 350: 1047-1059.
  • 22
    Endogenous Hormones and Breast Cancer Collaborative Group. Free estradiol and breast cancer risk in postmenopausal women: comparison of measured and calculated values. Cancer Epidemiol Biomarkers Prev. 2003; 12: 1457-1461.
  • 23
    Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005; 353: 229-237.
  • 24
    Calle EE, Rodriguez C, Jacobs EJ, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer. 2002; 94: 2490-2501.
  • 25
    Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999; 91: 1829-1846.
  • 26
    Merrill RM, Feuer EJ. Risk-adjusted cancer-incidence rates (United States). Cancer Causes Control. 1996; 7: 544-552.
  • 27
    Kniffin WD Jr, Baron JA, Barrett J, Birkmeyer JD, Anderson FA Jr. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med. 1994; 154: 861-866.
  • 28
    Stein PD, Kayali F, Olson RE. Estimated case fatality rate of pulmonary embolism, 1979 to 1998. Am J Cardiol. 2004; 93: 1197-1199.
  • 29
    Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003; 361: 296-300.
  • 30
    Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst. 1996; 88: 1834-1839.
  • 31
    Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than 5 years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001; 93: 684-690.
  • 32
    Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology. 2006; 71: 1-9.
  • 33
    Samsa GP, Bian J, Lipscomb J, Matchar DB. Epidemiology of recurrent cerebral infarction: a Medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke. 1999; 30: 338-349.
  • 34 Inc. Accessed July 27, 2010.
  • 35
    Hoover DR, Crystal S, Kumar R, Sambamoorthi U, Cantor JC. Medical expenditures during the last year of life: findings from the 1992-1996 Medicare Current Beneficiary Survey. Health Serv Res. 2002; 37: 1625-1642.
  • 36
    US Bureau of Labor Statistics. Consumer Price Index. Accessed July 20, 2010.
  • 37
    Tosteson AN, Stout NK, Fryback DG, et al. Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med. 2008; 148: 1-10.
  • 38
    Locker GY, Mansel R, Cella D, et al. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat. 2007; 106: 229-238.
  • 39
    Meadows ES, Klein R, Rousculp MD, Smolen L, Ohsfeldt RL, Johnston JA. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia [serial online]. BMC Womens Health. 2007; 7: 6.
  • 40
    Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data 1999-2006. Accessed September 2008.
  • 41
    Pinsky PF, Kramer BS, Reding D, Buys S. Reported family history of cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am J Epidemiol. 2003; 157: 792-799.
  • 42
    Col NF, Goldberg RJ, Orr RK, Erban JK, Fortin JM, Chlebowski RT. Survival impact of tamoxifen use for breast cancer risk reduction: projections from a patient-specific Markov model. Med Decis Making. 2002; 22: 386-393.
  • 43
    Cykert S, Phifer N, Hansen C. Tamoxifen for breast cancer prevention: a framework for clinical decisions. Obstet Gynecol. 2004; 104: 433-442.
  • 44
    Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992; 146: 473-481.
  • 45
    Loomes G, McKenzie L. The use of QALYs in health care decision making. Soc Sci Med. 1989; 28: 299-308.
  • 46
    Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol. 1999; 17: 1939-1955.
  • 47
    Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN. Chemoprevention of breast cancer: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2002; 137: 59-69.
  • 48
    Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: clinical implications. Oncologist. 2006; 11: 126-135.
  • 49
    Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005; 59: 97-102.
  • 50
    Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol. 2001; 8: 580-585.
  • 51
    Fabian CJ, Kimler BF. Is chemoprevention practical? Curr Breast Cancer Rep. 2009; 1: 48-53.
  • 52
    Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila). 2010; 3: 696-706.
  • 53
    Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation. Breast Cancer Res Treat. 2001; 65: 125-134.
  • 54
    Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008; 9: 45-53.
  • 55
    Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther. 2008; 8: 1377-1385.
  • 56
    Chlebowski RT, Anderson GL, Lane DS, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst. 2007; 99: 1695-1705.